Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films

ABSTRACT

A medicant composition is provided. The composition includes a film layer and a powder matrix layer. The powder matrix layer includes a medicant. The powder matrix layer is applied to the film layer by admixing particulate to form a powder matrix and by then applying the powder matrix to the film layer by any desired method. The composition of the powder matrix is varied to alter the dissolution rate of the medicant, the adhesion of the medicant composition, and other physical properties of the powder matrix. The powder matrix layer can be cured.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional of U.S. patent application Ser. No.11/836,758, filed on Aug. 9, 2007, which application is a divisional ofU.S. patent application Ser. No. 10/402,273, filed on Mar. 28, 2003,which are incorporated by reference herein in their entirety.

TECHNICAL FIELD

This invention pertains to edible compositions.

More particularly, the invention pertains to a film in which a medicantis applied as a powder.

In another respect, the invention pertains to a method for making a filmthat facilitates the incorporation with the film of a gel.

In a further respect, the invention pertains to a method for making afilm including a medicant that minimizes the exposure of the medicant inthe film to moisture, heat, and shear during the manufacturing process.

In still another respect, the invention pertains to a method for makinga film that facilitates stabilizing a medicant in the film.

In yet another respect, the invention pertains to a method for applyinga medicant to living cells in the body of an individual.

In yet still another respect, the invention pertains to a method forcuring a film.

BACKGROUND

A wide variety of edible compositions exist in nature, are grown, or aremanufactured. One particular kind of manufactured edible compositionscomprises lozenges, films, and other compositions that are intended tobe placed in and to dissolve or otherwise disassociate in the mouth.

U.S. Pat. No. 4,517,173 to Kizawa et al. (1985) discloses a film thatadheres to mucous membrane. The film includes at least three layers. Thelayers are a pharmaceutical layer, a poor water-soluble layer, and anintermediate layer.

The pharmaceutical layer is a material selected from the groupconsisting of predonisolone and allantoin together with water-solublecellulose derivatives. The cellulose derivatives are selected from thegroup consisting of hydroxypropyl cellulose, methyl cellulose, hydroxypropyl methyl cellulose and mixtures thereof.

The predonisolone, allantoin, and/or celluose derivatives form a thinfilm base. The poor water-soluble layer consists of water-solublecellulose derivative together with water-soluble components. Thewater-soluble components are selected from the group consisting ofshellac, higher fatty acids, and mixtures thereof. The intermediatelayer consists of water-soluble cellulose derivatives not containing apharmaceutical agent and not containing poor water soluble components.

Another embodiment of the film described in U.S. Pat. No. 4,517,173includes one layer of pharmaceutical agents and water-soluble highpolymer material. The other layer of the film consist of poorwater-soluble agents. A first solvent solution for forming thepharmaceutical agent and water-soluble high polymer material first layeris prepared. A second solvent solution for forming the poorwater-soluble agents second layer is prepared separately. The firstsolution is coated on a base plate having a favorable releasing nature.The solvent is removed from the solution to produce a first film layeron the base plate. The second solution is then coated on the firstlayer. The solvent is removed from the second solution. The solvent isremoved from the second solution to form the second film layer.

By way of example, in U.S. Pat. No. 4,517,173 a solution for the filmbase agent for preparing the pharmaceutical layer is prepared bydissolving hydropropyl cellulose and macrogol-400 (polyethylene glycol)in ethyl alcohol and distilled water. The distilled water containsdissolved predonisolone. A solution for preparing the poor water-solublelayer is prepared by dissolving hydroxypropyl cellulose, magrogol, andshellac in ethyl alcohol. The solution for the first base agent for theintermediate layer is prepared by dissolving hydroxypropyl cellulose andmagrogol in ethyl alcohol.

U.S. Pat. No. 5,948,430 to Zerbe et al. (1999) discloses a monolayerfilm formed from a mucoadhesive composition. The mucoadhesivecomposition comprises at least one water-soluble polymer, at least onemember selected from the group consisting of a polyalcohol, a surfactantand a plasticizer; at least one cosmetic or pharmaceutically activeingredient; and a flavoring agent. The film rapidly softens andcompletely disintegrates in the oral environment and has a dry filmthickness suitable for application in the mouth without causing adversefeeling in the mouth. During preparation of the film, the polyalcohol,surfactants, plasticizers, and possible other ingredients except thewater-soluble or water-dispersible polymer(s) are dissolved in asufficient amount of compatible solvent. The solvent can, for example,include water and/or alcohol. Once a clear solution is formed, thewater-dispersible polymer or mixture of water dispersible polymers isslowly added with stirring, and heated if necessary, until a clear andhomogeneous solution is formed. Active ingredients and flavors areadded. The resulting solution is coated onto a suitable carrier materialand dried to produce a film. The carrier material has a surface tensionthat allows the polymer solution to spread evenly across the intendedcoating width without soaking in to form a bond between the two. Thecarrier material can, for example, comprise non-siloconized polyethyleneterephthalate film, on-siliconized kraft paper, polyethylene-impregnatedkraft paper, or non-siliconized polyethylene film. The thickness of thefilm can vary between 5 and 200 um. Drying of the film is done in ahigh-temperature air-bath using a drying oven, drying tunnel, vacuumdrier, or any other suitable drying equipment that does not adverselyaffect the active ingredient(s) or flavor of the film. A film thicknessgreater than 70 um is avoided so that an adverse feeling is not producedin the mouth.

U.S. Pat. No. 5,166,233 to Kuroya et al. (1992) describes a film that isapplicable to the oral mucosa. The film comprises a homogeneous mixture.The homogenous mixture comprises a vinyl acetate homopolymer, an acrylicacid polymer, and a cellulose derivative capable of being dissolved inor swollen with water and a lower alcohol. The film also contains a saltor base to neutralize the acrylic acid polymer. The salt or base ispresent in an amount of from 0.03 to 0.2 equivalent to the acrylic acidpolymer. The acrylic acid polymer and cellulose derivative are presentat a weight ratio of from 1:9 to 9:1. The lower alcohol is methanol orethanol. By the way of example, one procedure for preparing a filmcomprises mixing a vinyl acetate homopolymer, a carboxyvinyl polymer,and a hydroxypropyl cellulose to a 1:9 water/methanol solvent mixture toproduce a film-forming composition. The film-forming composition isapplied to a silicone-release paper, dried, and stripped off to obtain a30 .mu.m thick adhesive film.

U.S. Pat. No. 5,047,244 to Sanvordeker, et al. (1991) describes amucoadhesive carrier. The carrier allows controlled release of atherapeutic agent via mucosal tissue. The carrier is claimed as a“therapeutic dosage”. For example, in one claim the “therapeutic dosage”comprises an anhydrous but hydratable monolithic polymer matrixcontaining amorphous fumed silica and a therapeutic agent. The polymermatrix defines a mucoadhesive face. A water-insoluble barrier layer issecured to the polymer matrix. The barrier layer defines a non-adhesiveface. The therapeutic agent is dehydroepiandrosterone. The polymer ispolyethylene glycol. The polyethylene glycol has a number averagemolecular weight of about 4,000. The weight ratio ofdehydroepiandrosterone to polyethylene glycol is about 1:4. By way ofexample, the polymer matrix and barrier film are prepared separately.

The polymer matrix is prepared by dissolving the therapeutic agent inpolyethylene glycol. The polyethylene glycol is melted at 160 degrees F.The powder therapeutic agent is slowly added to the molten polyethyloeneglycol and the glycol is stirred until the therapeutic agent iscompletely dissolved. The resulting composition is poured onto flataluminum foil and allowed to solidify to form a mucosal composition. Themucosal composition is finely ground to a powder of about 60 to 80 meshand blended with other matrix forming hydrophilic and hydrophobicexcipients. Such excipients can comprise glyceryl behenate, polyvinylalcohol, dicalcium phosphate dihydrate, hydroxypropyl cellulose andsilica. Additional polyethylene glycol can be added. A granulationprocess utilizing an organic solvent or water can be used to prepare,dry, and obtain granules having a size in the range of 40 to 200 mesh.

The barrier film is prepared using constituents from the polymer matrix,except the barrier film does not include a therapeutic agent.

The components of the polymer matrix and barrier film are compressedtogether to obtain a bi-laminate mucoadhesive carrier.

U.S. Pat. No. 4,876,092 to Mizobuchi, et al. describes a sheet-shapedadhesive pharmaceutical preparation. The preparation can adhere to theoral cavity. The preparation comprises an adhesive layer and a carrierlayer. The adhesive layer includes a carboxyvinyl polymer, awater-soluble methacrylic copolymer, a polyhydric alcohol, and apharmaceutically active agent. The carrier layer is water-impermeableand water-insoluble. The carrier layer includes a pharmaceuticallyacceptable water-insoluble, film-forming high molecular weight compoundand includes a plasticizer. The ingredients of the adhesive layer aresubstantially released from one side of the sheet-shaped pharmaceuticalpreparation. The ingredients are absorbed through the mucous membrane orteethridge to which the preparation is adhered in the oral cavity. Byway of example, the adhesive layer is prepared by producing an adhesivelayer mixture. The adhesive layer mixture is prepared by mixing thecomponents for the adhesive layer in an appropriate solvent like ethylalcohol. The resulting mixture is spread onto a release paper in adesired thickness in a conventional manner and is dried to produce asheet-like adhesive layer. The components for the carrier layer aredissolved in an appropriate solvent to produce a carrier layer mixture.The resulting carrier layer mixture is spread onto the sheet-likeadhesive layer and dried.

U.S. Patent Application U.S. 2002/0131990 to Barkalow et al. (2002)discloses a pullulan free edible film composition. The film comprises aneffective amount of at least one film forming agent; an effective amountof at least one bulk filler agent; and, an effective amount of at leastone plasticizing agent. By way of example, the film is produced byadding LustreClear (a composition by FMC Corporation for use as a clearcoating for pharmaceutical tablets) to water to produce a coatingmixture. LustreClear contains microcrystalline cellulose, carrageenan,polyethylene glycol, hydroxyethyl cellulose and maltodextrin. Thecoating mixture is heated to 50 degrees C. and other ingredients areadded. While the mixture is warm, the mixture is poured onto a glassplate and drawn down to form a thin film with a 0.08 inch blade. Theresulting film composition is dried at 50 degrees C. for about fifteenminutes.

U.S. Patent Application U.S. 2001/0022964 to Leung et al. (2001)discloses a consumable film. The film is adapted to adhere to anddissolve in a mouth of a consumer. The film comprises at least one watersoluble polymer and an antimicrobial effective amount of at least oneessential oil selected from the group consisting of thymol, methylsalicylate, eucalyptol and menthol. By way of example, a film isprepared as follows. Xanthan gum, locust bean gum, carrageenan andpullulan are mixed and hydrated in hot purified water to form a gel. Thegel is stored in a refrigerator overnight at a temperature ofapproximately four degrees C. to form preparation A. Coloring agents,copper gluconate, and sweetener are added to and dissolved in purifiedwater to form preparation B. Preparation B is mixed with preparation Ato form preparation C. Flavoring agents and oils (including coolingagent, thymol, methyl salicylate, eucalyptol and menthol) are mixed toform preparation D. Polysorbate 80 and Atmos 300 are added topreparation D and mixed to form preparation E. Preparation E is added topreparation C and mixed to form preparation F. Preparation F is pouredon a mold and cast to form a film of desired thickness at roomtemperature. The film is dried under warm air.

The prior art edible films and production processes each have desirableaspects. They also have disadvantages. One disadvantage is that theprior art processes may expose medicants or actives or othercompositions to water or another liquid during production of the ediblefilms. Many medicants or other compositions are unstable in the presenceof water or other liquids. A second disadvantage of prior art processesis that the production process may subject a medicant or othercomposition to shear. Shear can damage the medicant. Shear occurs when amixing blade or other member forces a medicant particle intermediate theblade and another solid member, generating friction and heat. A thirddisadvantage of prior art processes is that they may require theapplication of heat at temperatures or over extended periods of timethat can degrade or undesirably alter the stability or properties of amedicant or other composition. A fourth potential disadvantage of priorart processes is that they may not permit, with minimal effort, thedissolution rate of a medicant or other composition to be varied. Afifth potential disadvantage of prior art processes is that they maymake use of a hydrophilic component at higher concentrations impracticalbecause during production the hydrophilic component rapidly absorbswater and become difficult to process. A sixth potential disadvantage ofprior art processes is that the edible films produced are primarilysuitable only for use in the oral cavity and not for use on livingcells. A seventh potential disadvantage of prior art processes is thatheat alone can not, practically speaking, be used to form a smoothcoating on an edible film. An eighth potential disadvantage of prior artprocesses is that they require the use of a solvent to produce a layerincluding a medicant or other desired composition. A ninth potentialdisadvantage of the prior art processes is that they require thecompatibility of a medicant with other components in a solvent solutionto be taken into account.

Accordingly, it would be highly desirable to provide an improved ediblefilm and process for making the same that would minimize the risk that amedicant or other composition is degraded or otherwise damaged by heat,shear, or moisture; that would permit the dissolution rate of a medicantto be readily varied, that would permit the ready use of a hydrophiliccomposition, that could be utilized on live cells, that would facilitatethe use of heat to form a coating on an edible film, and that would notrequire the use of a solvent to mix compositions to form amedicant-containing layer.

I have discovered an improved film and method for making the same. Thefilm can be used on living cells. Formation of the medicant-containinglayer in the film does not require a solvent and minimizes thelikelihood of damage from heat and shear. The rate of dissolution ordelivery of the medicant by the film can be readily adjusted. Themedicant-containing layer, while minimizing the likelihood of heatinduced medicant damage, permits heat to be utilized to form a coatingon the edible film. Hydrophilic components can be readily incorporatedin larger concentrations during production of the medicant-containinglayer.

SUMMARY

I have also discovered an improved composition for delivering a medicantin the oral cavity. The composition includes an applied coating and afilm layer.

The film layer is made from any polymer, softener, filler, matrix, orother composition. The film has an acceptable dissolution rate in theoral cavity for a particular thickness of film. For example, if the filmhas a thickness of 50 microns, it may be desirable for the film todissolve in the oral cavity within about fifteen seconds. Or it may bedesirable for the film to dissolve more slowly. By way of example, andnot limitation, the film can be made with pullulan, modified starch,pectin, carageenan, a maltrodextrin, or alginate.

The applied coating is a powder matrix including one or more medicants.The medicant can be contained in a powder carrier, or can itself be apowder. One advantage of the powder matrix is that it ordinarily doesnot require the use of a solvent. Another advantage of the powder matrixis that it ordinarily can, if desired, include in addition to themedicant a variety of different auxiliary compositions. A furtheradvantage of the powder matrix is that it can be admixed in a fluidizedbed that minimizes the generation of shear and heat. In a fluidized beddry air or another gas is dispersed upwardly through a plurality ofopenings to suspend and intermix particulate. Any desired means can beused to admix powders. Another advantage of mixing or suspending powderin a fluidized bed is that the dry air suspending the powder particlestends to prevent agglomeration of the particles. The admixed powdermatrix can also be stored (i.e., suspended) in the fluidized bed, priorto the application of the admixed powder matrix to the film layer. Thepowder matrix can be applied in any desired manner, including sifting,screening, atomization, static, mechanical agitation, etc. For example,the powder matrix can be atomized through a Nordson or similar staticspray gun using compressed air. One such gun creates a fine mist sprayof powder particles. The gun statically electrically charges the powderparticles so they adhere to a surface of the film layer that isreceiving the powder particles. Another process for applying the powderparticles is to admix the particles with a liquid carrier to form aparticle-liquid solution. The particle-liquid solution is sprayed on thefilm layer. The liquid carrier evaporates, leaving the powder particleson the film. The liquid carrier preferably does not cause the powderparticles to dissolve in the liquid carrier.

One auxiliary composition that can be included in the powder matrix withthe medicant is a composition that dissolves slowly over a selectedperiod of time. Such an auxiliary dissolution control composition can beutilized to slow the release of medicant in the oral cavity. Examples ofthis kind of auxiliary composition are, without limitation, gel formingcompositions like carrageenan, gelatin, alignates, pullulan, PVP, andother hydrophilic materials; cyclodextrin; and, inert materials likecalcium and fibers. For example, the fibers can comprisecarboxymethylcellulose.

Another auxiliary composition the can be included in the powder matrixwith the medicant is an absorption composition that absorbs water orsaliva. Such an auxiliary absorption composition can be also be used toslow the release of medicant, and/or, to form a gel. The gel can, ifdesired, cause the strip to become chewable, similar to a very softjelly-bean. As used herein, an auxiliary composition is termed a gel if,when it is placed in the oral cavity or in contact with another sourceof bodily liquid, (1) the auxiliary composition absorbs at least fourtimes it weight of water or of saliva or other aqueous solution in aselected period of time, or (2) the auxiliary composition swells to atleast three times its thickness in a selected period of time. Theselected period of time can vary but preferably is from five seconds tofifteen minutes, most preferably five seconds to five minutes. Examplesof gel auxiliary compositions include, without limitation,carboxymethylcellulose, pectin, modified starches, gelatin, andcarrageenan. These compositions can be used alone or in combination. Oneadvantage of a gel is that it tends to slow the dissolution of themedicant and to maintain the medicant in the oral cavity for a longerperiod of time.

A further auxiliary composition that can be included in the powdermatrix is a composition that, when placed in the oral cavity in contactwith the mucosa therein, adheres to the mucosa. The concentration ofsuch auxiliary adhesion compositions in the powder' matrix can beadjusted to vary the length of time that the film adheres to the mucosaor to vary the adhesive forces generated between the film and mucosa.The auxiliary adhesion compositions adhere to the oral mucosa or tomucosa or tissue in other parts of the body, including the mouth, nose,eyes, vagina, and rectum. Examples of auxiliary adhesion compositionsinclude carboxymethycellulose, polyvinyl alcohol, polyvinyl pyrrolidone(povidone), sodiumalginate, methyl cellulose, hydroxyl propyl cellulose,hydroxypropylmethyl cellulose, polyethylene glycols, carbopol,polycarbophil, carboxyvinyl copolymers, propylene glycol alginate,alginic acid, methyl methacrylate copolymers, tragacanth gum, guar gum,karaya gum, ethylene vinyl cetate, dimenthylpolysiloxanes,polyoxyalkylene block copolymers, and hydroxyethylmethacrylatecopolymers. All examples of composition provided herein are givenwithout limiting the use or inclusion of other comparable orfunctionally equivalent compositions even though such comparable orfunctionally equivalent compositions are not listed.

Still another auxiliary composition that can be included in the powdermatrix is a flow composition that, when subjected to a curing process,flows to form a smoother or shinier coating on the exterior of the filmlayer. One preferred curing process is heating the film layer withpowder coating to a selected temperature above 76 degrees F. to causethe auxiliary flow composition to soften and flow. Examples of this kindof auxiliary composition are lipids (including various animal andvegetable fats) waxes, particularly low melting point waxes, andpolyols, particularly low melting point polyols that can be admixed inpowder form or than can included be in powder particles containing amedicant or other compositions. The medicant itself, may also have theproperty of flowing at an elevated temperature in excess of 76 degreesF. to form a smoother or shinier coating.

Other auxiliary compositions that can be included in the powder matrixinclude, without limitation, bulking agents, fillers, pigments(coloring), flavorings, and sweeteners.

Combinations of auxiliary compositions can be included in the powdermatrix to achieve a desired function. For example, if it is desired toslow the dissolution of a medicant, less soluble fillers and fibers canbe included in the powder matrix along with a high concentration ofpolymers that have a very high degree of ability to adhere to the oralmucosa lining the mouth.

The powder matrix is normally administered to the film layer to form theapplied coating after the film layer has been manufactured.

The dry powder matrix will normally contain a minor amount of retainedor bound water or other liquid, typically less than about ten percent byweight. The level of moisture in the powder matrix normally should notcause the powder particles to stick or adhere to one another duringintermixing of powders to form the powder matrix and during applicationof the powder matrix to the film layer.

A medicant is an agent that cures, treats, or prevents a disease ordisease symptom or condition in a body or portion of a body. By way ofexample, and not limitation medicants include anti-inflammatory steroidssuch as predonisone, predonisolone, predonisolone acetate,hydrocortisone, triamcinolone, dexamethasone, and betamethasone;anti-inflammatory anodynes such as aspirin, aminopyrin, acetoaminophen,ibufenac, ibuprofen, indomethasine, colehicine, sulpyrine, mephenamicacid, phenacetin, phenylbutazone, fulfenamic acid, and probenecid;anti-inflammatory enzymes such as (a)-chymotrysin; anti-histamine agentssuch as diphenhydramine-hydrocholride, and chlorophenylamine maleate;oral sterilizing agents such as chlorohexydine-hydrochloride,cetylpyridinium-chloride, hexylresorcin and nitro-furazone; antibitocmaterials such as penicillin or its dervatives, cephaphalosporinderivative, erythromycine, tetracycline hydrochloride, furadiomycin, andleucomycin; chemically therapeutic agents such as sulfamethyzole andnalidixic; cardiac strengthening agents such as digatalis and digoxin;blood vein dilating agents such as nitroglycerine andpapaverine-hydrochloride; local narcotic agents such as lidocain andprocain-hydrochloride; cough curing agents such as codeine phosphate andbisorlvon; sore throat and mouth treatment agents such as phenol andbenzocaine; periodontal disease treatment agents including peptides;digesting organ curing agents such as azulene, phenovalin, pepsin, andvitamin U; enzymes such as lysozyme-chloride or trypsin; anti-diabeticagents such as insulin; blood pressure depressing agents; tranquilizers;stypic agents; sexual hormones; agents for curing virulent carcinoma orulcers; vitamins; and minerals. The amount of medicant incorporated withthe film layer depends on the kind of drug and is usually between 0.001to 20% by weight, but can be less or more if necessary to achieve thedesired effect.

By way of example, and not limitation, the film layer can be producedusing a highly water-soluble polymer comprising a natural or syntheticwater-soluble polymer. The polymer preferably has good film moldability,produces a soft flexible film, and is safe for human consumption. Onesuch polymer can be a water-soluble cellulose derivative likehydroxypropyl cellulose (HPC), methyl cellulose, hydroxypropylalkylcellulose, carboxymethyl cellulose or the salt of carboxymethylcellulose. Or, the polymer can comprise an acrylic acid copolymer or itssodium, potassium or ammonium salt. The acrylic acid copolymer or itssalt can be combined with methacrylic acid, styrene or vinyl type ofether as a comonomer, poly vinyl alcohol, poly vinyl pyrrolidone,polyalkylene blycol, hydroxy propyl starch, alginic acid or its salt,poly-saccharide or its derivatives such as trangacanth, bum gelatin,collagen, denatured gelatin, and collagen treated with succinic acid oranhydrous phthalic acid. By way of example, the following can beincluded in the powder matrix as adhesives: poorly water-solublecellulose derivatives including ethyl cellulose, cellulose acetate andbutyl cellulose; shellac; higher fatty acids including steric acid andpalmitic acid. The following can also, without limitation, be used toproduce the film layer: pullulan, maltodextrin, pectin, alginates,carrageenan, guar gum, other gelatins, etc.

Bulking agents that can be included in the powder matrix include, by wayof example and not limitation, avicel, sugar alchohols including manitoland sorbitol and xylitol and isomalt, lactic sugar, sorbitol dextrin,starch, anhydrous calcium phosphate, calcium carbonate, magnesiumtrisilicate, silica, and amylase.

The size of particulate in the powder matrix can vary as desired, but ispreferably in the range of 10 mesh to 400 mesh or finer, preferably 40mesh to 300 mesh.

The thickness of the film layer can vary as desired, but typically is inthe range of 0.01 mm to 3.00 mm, preferably 0.03 mm to 1.00 mm.

The powder matrix can be applied to one or both sides of the film layer.The film layer includes upper outer surface on the top of the film layerand includes a lower outer surface on the bottom of the film. The upperouter surface is generally parallel to the lower outer surface. The topof the film is generally parallel to the bottom of the film. Thethickness of the powder matrix layer can vary as desired, but ispreferably in the range of 0.001 mm to 3.00 mm, preferably 0.01 mm to1.00 mm.

If desired, after the powder matrix layer is applied to the film layer,an additional layer or layers can be applied over the powder matrixlayer to seal the powder matrix layer, slow the dissolution of themedicant from the powder matrix layer, etc.

If desired, multiple powder matrix layers can be applied to the filmlayer. The film layer can comprise a laminate of two or more layers.Methods for producing the film layer and incorporating plasticizers,bulking agents, taste modifying agents, pigments, etc. in the film layerare well known in the art and not described in detail herein. Since themedicant is being applied to the film layer in a dry powder form, thelikelihood of adverse interactions between the medicant and compositionscomprising the film layer is lessened.

The following examples are provided by way of illustration, and notlimitation, of the invention.

EXAMPLE I

3.4 g of hydropropyl cellulose and 0.4 ml of macrogol-400 (polyethyleneglycol) are dissolved in 60 g of ethyl alcohol to produce acellulose-alcohol solution. Nine milliliters of distilled watercontaining 90 mg of dissolved predonisolone is added to thecellulose-alcohol solution to produce a film forming composition. Thefilm forming composition is poured into a film molding frame placed on ateflon plate. The area of teflon plate circumscribed by the frame is 9.5square centimeters. The film forming composition is dried to form a filmlayer. The film layer includes an upper outer surface on top of the filmlayer and includes a lower outer surface on the bottom of the filmlayer. The lower outer surface is generally parallel to the upper outersurface. The film layer has a thickness of 40 microns. As noted, anydesired prior art process and/or materials can be utilized to producethe film layer.

Benzocaine powder (as a medicant) is combined withcarboxymethylcellulose powder (as an adhesive), modified food starch (asa bulking agent), carrageenan (as adhesive), sucralose (intensesweetener), talc (as flow/partitioning agent), and menthol (as amedicant) in a fluidized bed container to form a powder matrix. Theresulting powder matrix includes 3.76% by weight of benzocaine powder,2.6% by weight percent of carboxymethylcellulose powder, 85.43% byweight of modified food starch, 3.76% by weight menthol, 2% by weightcarrageenan, 0.45% by weight sucralose, and 2.0% by weight magnesiumtrisilicate (talc). The powder matrix is drawn from the fluidized bedcontainer and is applied to the upper exposed surface of the film layerto a substantially uniform thickness of 60 microns. The powder matrix isatomized through a Nordson or similar static spray gun using compressedair. See, for example Nordson Corporation's KINETIC™ spray systems(www.nordson.com). The gun creates a fine mist spray of powderparticles. The gun statically electrically charges the powder particlesso they adhere to the upper surface of the film layer. If desired thepowder matrix can also be applied to the lower or bottom surface of thefilm layer. The powder matrix layer and film layer together comprise amedicant composition. The medicant composition can be applied to mucousmembrane at various areas of the body.

EXAMPLE II

A film layer is prepared as follows. Xanthan gum (1.5% by weight),locust bean gum (1.5% by weight), carrageenan (1% by weight) andpullulan (9.5% by weight) are mixed and hydrated in hot purified water(86.5% by weight) to form a gel. The gel is stored in a refrigeratorovernight at a temperature of approximately four degrees C. to form afilm layer. The film layer has a thickness of 55 microns.

Coral calcium powder (as a medicant) is combined withcarboxymethylcellulose powder (as an adhesive), modified food starch (asa bulking agent), carrageenan (as adhesive), sucralose (intensesweetener), talc (as flow/partitioning agent), menthol (as a medicant),and a lipid in a fluidized-bed container to produce a powder matrix. Thelipid is BENEFAT™. BENEFAT is used by DANISCO to designate salatrim,which is the abbreviation for long and short chain triglyceridemolecules. The resulting powder matrix includes 3.76% by weight of coralcalcium powder, 2.6% by weight percent of carboxymethylcellulose powder,73.43% by weight of modified food starch, 3.76% by weight menthol, 2% byweight carrageenan, 0.45% by weight sucralose, 2.0% by weight magnesiumtrisilicate, and 12% by weight of the lipid. The lipid preferably is inpowder form. If the lipid initially is in liquid form, it can be platedon a particulate absorbent to produce a flowable powder. The particulateabsorbent could, for example, be talc.

The powder matrix is drawn from the fluidized bed container and isapplied to the upper exposed surface of the film layer to a uniformthickness of 150 microns. The powder matrix is atomized through aNordson or similar static spray gun using compressed air. The powdermatrix layer and film layer together comprise a medicant composition.

Ideally, the melting point of the lipid is close to temperature at whichthe film layer is dried. For example, the film layer (along with thepowder matrix layer applied to the film layer) is typically dried atabout 200 degrees F. The lipid preferably has a softening point ormelting temperature of about 200 degrees F. so that the temperature atwhich the film layer is dried is the ideal softening point for thelipid. If the melting temperature of the lipid is too low in comparisonto the temperature at which the film layer is dried, the lipid can meltand run off the film.

The medicant composition is cured using any desired heat treatmentprocess. The presently preferred process comprises a first step duringwhich the medicant composition is heated by a microwave or infraredtransmitter. The time spent by the medicant composition under thetransmitter varies depending on the amount of moisture to be removed,but typically is fifteen to twenty seconds. The microwave/infraredbombardment facilitates proper heating of the film layer by generatingheat in the film layer. During the second step of the heat treatmentprocess the medicant composition is heated to 200 degrees F. in aconvection oven for a desired length of time to dry the medicantcomposition. The length of time the medicant composition is in theconvection oven can vary but is typically presently about three to fourminutes. During the foregoing heat treatment process, the lipid powderparticles soften and flow to produce a smoother powder matrix layer onthe film layer. The smoother powder matrix layer also improves the feelto an individual of the medicant composition in the mouth because themedicant composition is not as dry on the tongue.

EXAMPLE III

3.4 g of hydropropyl cellulose and 0.4 ml of macrogol-400 (polyethyleneglycol) are dissolved in 60 g of ethyl alcohol to produce acellulose-alcohol solution. Nine milliliters of distilled watercontaining 90 mg of dissolved predonisolone is added to thecellulose-alcohol solution to produce a film forming composition. Thefilm forming composition is poured into a film molding frame placed on ateflon plate. The area of teflon plate circumscribed by the frame is 9.5square centimeters. The film forming composition is dried to form a filmlayer. The film layer has a thickness of 30 microns.

Penicillin or another antibiotic (as a medicant) suitable for treatingconjunctivitis is combined with carboxymethylcellulose powder (as anadhesive) in a fluidized bed container. The resulting powder matrixincludes 5.00% by weight of the antibiotic powder, and 95% by weight ofcarboxymethylcellulose powder. The powder matrix is drawn from thefluidized bed container and is applied to the upper exposed surface ofthe film layer to a substantially uniform thickness of 5.0 microns. Thepowder matrix is applied with a Nordson or similar static spray gun.

If desired, the powder matrix can also be applied to the lower or bottomsurface of the film layer. The powder matrix layer and film layercomprise a medicant. A circular piece three-eighths inch in diameter iscut from the medicant composition. The circular piece is 35 micronsthick and includes a portion of the film layer and a portion of thepowder matrix layer. The circular piece is placed in an individual's eyewith the powder matrix layer contacting the tear layer of the eye. Theamount of adhesive in the powder matrix layer is gauged so that thepowder matrix layer does not absorb moisture too rapidly from the tearlayer of the individual's eye.

EXAMPLE IV

A contact lens is coated with a medicant. The medicant is released intoan individual's eye when the contact lens is inserted in the eye.

EXAMPLE V

A contact lens is impregnated with a medicant. The medicant is graduallyreleased into an individual's eye when the contact lens is inserted inthe eye.

EXAMPLE VI

3.4 g of hydropropyl cellulose and 0.4 ml of macrogol-400 (polyethyleneglycol) are dissolved in 60 g of ethyl alcohol to produce acellulose-alcohol solution. Nine milliliters of distilled watercontaining 90 mg of dissolved predonisolone is added to thecellulose-alcohol solution to produce a film forming composition. Thefilm forming composition is poured into a film molding frame placed on ateflon plate. The area of teflon plate circumscribed by the frame is 9.5square centimeters. The film forming composition is dried to form a filmlayer. The film layer has a thickness of 50 microns.

Coral calcium powder (as a medicant) is combined withcarboxymethylcellulose powder (as a fiber adhesive), modified foodstarch (as a soluble bulking agent), carrageenan (as adhesive), pullulan(as a polymer), calcium carbonate (as a non-soluble filler/bulkingagent), sucralose (intense sweetener), talc (as flow/partitioningagent), and menthol (as a medicant) in a fluidized bed container. Theresulting powder matrix includes 3.76% by weight of benzocaine powder,5.2% by weight percent of carboxymethylcellusoe powder, 38.33% by weightof modified food starch, 5.0% by weight pullulan, 3.76% by weightmenthol, 4% by weight carrageenan, 2.5% by weight talc, 0.45% by weightsucralose, 35% by weight calcium carbonate, and 2.0% by weight magnesiumtrisilicate.

The filler, fiber, and polymer components of the powder matrix are usedto slow the dissolution of the medicant when the resulting medicantcomposition is placed in the oral mucosa of an individual.

The powder matrix is drawn from the fluidized bed container and isapplied to the upper exposed surface of the film layer to asubstantially uniform thickness of 80 microns. The powder matrix isatomized through a Nordson or similar static spray gun using compressedair. The powder matrix layer and film layer together comprise a medicantcomposition.

Having described my invention in such terms as to enable those of skillin the art to make and practice it, and having described the presentlypreferred embodiments thereof, I Claim: 1-20. (canceled)
 21. A method ofdelivering a medicant in the oral cavity of a mammal, comprisingdisposing within the oral cavity of the mammal a thin film compositioncomprising the medicant, the thin film composition being prepared by amethod comprising the steps of: providing a film layer comprising awater-soluble polymer selected from the group consisting of pullulan,modified starch, pectin, carrageenan, a maltrodextrin, and an alginate;or any combination thereof; applying a coating to said film layerwithout use of a solvent, wherein said coating comprises a powdermatrix; wherein the powder matrix, prior to application to the filmlayer, is admixed in a fluidized bed that minimizes the generation ofshear and heat; wherein the powder matrix comprises a medicant; thepowder matrix further comprising a composition that, when placed in theoral cavity in contact with the mucosa therein, cases the thin filmcomposition to adhere to the mucosa.
 22. The method of claim 21, whereinthe powder matrix is applied to the film layer by use of a static spraygun using compressed air.
 23. The method of claim 21, wherein afterplacing the thin film composition within the oral cavity of the mammal,the thin film composition adheres to the mucosa of the oral cavity. 24.The method of claim 23, wherein the film dissolves within the oralcavity in a period of less than about 15 seconds.
 25. The method ofclaim 21, wherein the thin film composition further comprises anauxiliary dissolution control composition that acts to slow the releaseof the medicant in the oral cavity.
 26. The method of claim 25, whereinthe auxiliary dissolution control composition comprises carrageenan,gelatin, alginates, pullulan, PCP, cyclodextrin, calcium, orcarboxymethylcellulose, or any combination thereof
 27. The method ofclaim 21, wherein the thin film composition comprises an absorptioncomposition that absorbs water or saliva.
 28. The method of claims 27,wherein the absorption composition comprises carboxymethylcellulose,pectin, a modified starch, gelatin, or carrageenan, or any combinationthereof
 29. The method of claim 21, wherein the thin film composition isformed by the process of claim 21 further comprising a curing process,wherein the thin film composition comprises a flow composition that uponheating of the thin film composition to a selected temperature about 76degrees F. causes the flow composition to soften and flow to form asmoother or shinier coating on the exterior of the film compared to afilm prepared by an analogous process but lacking the curing of the flowcomposition.
 30. The method of claim 29, wherein the flow compositionscomprises a lipid, a wax, or a polyol, or any combination thereof. 31.The method of claim 21, wherein the medicant is an anti-inflammatorysteroid.
 32. The method of claim 31, wherein the steroid is predonisone,predonisolone, predonisolone acetate, hydrocortisone, triamcinolone,dexomethanose or betamethasone.
 33. The method of claim 21, wherein themedicant is an anti-inflammatory anodyne.
 34. The method of claim 33,wherein the anodyne is aspirin, aminopyrin, acetoaminophen, ibufenac,ibuprofen, indomethacin, colchicine, sulpyrine, mephenamic acid,phenacetin, phenylbutazone, fulfenamic aicd, or probenecid.
 35. Themethod of claim 21, wherein the medicant is an anti-histamine.
 36. Themethod of claim 35, wherein the anti-histamine is diphenhydramine orchlorpheniramine.
 37. The method of claim 21, wherein the medicant is anoral sterilizing agent.
 38. The method of claim 37, wherein the oralsterilizing agent is chlorohexydine-hydrochloride,cetylpyridinium-chloride, hexylresorcin, or nitro-furazone.
 39. Themethod of claim 21, wherein the medicant is an antibiotic.
 40. Themethod of claim 39, wherein the antibiotic is a penicillin, acephalosporine, erythromycine, tetracycline, furadiomycin, orleucomycin.